Publikation

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.

Wissenschaftlicher Artikel/Review - 13.10.2024

Bereiche
PubMed
DOI
Kontakt

Zitation
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U, Crysandt M, Jost E, Thol F, Heuser M, Götze K, Schlenk R, Salih H, Schittenhelm M, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kuendgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May A, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. Eur J Haematol 2024
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Eur J Haematol 2024
Veröffentlichungsdatum
13.10.2024
eISSN (Online)
1600-0609
Kurzbeschreibung/Zielsetzung

In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also in patients with adverse-risk genetics, without adding toxicity. We performed a post hoc analysis to determine the predictive impact of TP53 status. Despite a nominally higher ORR, the clinically meaningful survival benefit when adding ATRA to DEC was diminished, but not completely negated, in TP53-mutated patients. Indeed, 2 out of 14 TP53-mutated patients (14%) randomized to a DEC + ATRA-containing regimen lived for > 36 months. Further studies of ATRA combined with hypomethylating agents appear warranted in non-M3 AML patients ineligible for HMA/venetoclax therapy. Trial Registration: ClinicalTrials.gov identifier: NCT00867672.